Hostname: page-component-78c5997874-j824f Total loading time: 0 Render date: 2024-11-06T04:00:11.373Z Has data issue: false hasContentIssue false
  • English
  • Français

The use of Tranquillizers in Psychiatry

Published online by Cambridge University Press:  08 February 2018

Paul H. Hoch
Paul H. Hoch*
Affiliation:
Commissioner of Mental Hygiene, State of New York Professor of Clinical Psychiatry, Columbia University
Get access Rights & Permissions [Opens in a new window]

Extract

I should like to discuss some of the clinical aspects of the tranquillizing drugs, but without going into great detail as to the many theoretical considerations in biochemistry, physiology, pharmacology, etc. which have been ventilated so often in connection with this form of treatment.

Type
Anglo-American Symposium
Information
Journal of Mental Science , Volume 104 , Issue 435 , April 1958 , pp. 566 - 572
Copyright
Copyright © Royal College of Psychiatrists, 1958 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Annals of the New York Academy of Sciences, “Reserpine in the Treatment of Neuropsychiatric, Neurological, and Related Clinical Problems”, 61, Art. 1, pp. 1–280. New York. 15 April, 1955.Google Scholar
2. Chlorpromazine and Mental Health. Proceedings of the Symposium held under the auspices of Smith, Kline, and French Laboratories, 6 June, 1955. Warwick Hotel, Philadelphia, Pa., 1955. Philadelphia: Lea and Febiger.Google Scholar
3. Delay, J., and Deniker, P., “38 Cases of Psychoses under Prolonged and Continuous R.P.4560 Treatment”, Compte rendu du Congrès des Méd. Aliénistes et Neurologistes, Luxembourg, 21–27 July, 1952. pp. 7–18.Google Scholar
4. Idem , “Use in Psychiatric Therapy of a Phenothiazine with Selective Central Action (R.P.4560)”, Ann. Mèd.-Psychol., 1952, 110, 112.Google Scholar
5. Elkes, J., and Elkes, C., “Effect of Chlorpromazine on the Behaviour of Chronically Overactive Psychotic Patients”, Brit. Med. J., 1954, ii, 560.Google Scholar
6. Hoch, P. H., Malitz, S., and Lesse, S., “A Two-Year Evaluation of Chlorpromazine in Clinical Research and Practice”, Amer. J. Psychiat., 1956, 113, 540.Google Scholar
7. Idem , “New Drug Therapy in Psychiatry: Clinical Uses and Abuses in Mental Disorders”, N. Y. Acad. Med. Bull., 1957, 33, 474.Google Scholar
8. Idem , “The Production and Alleviation of Mental Abnormalities by Drugs”, XXth International Congress, Brussels, Belgium. 1956. St. Catherine's Press.Google Scholar
9. Kinross-Wright, V., “Chlorpromazine Treatment of Mental Disorders”, American Psychiatrical Association at 121st Annual Meeting. Amer. Assoc. Adv. Sci., Berkeley, Calif, 1954.Google Scholar
10. Lehmann, H. E., “Therapeutic Results with Chlorpromazine (Largactil) in Psychiatric Conditions”, Canad. M.A.J., 1955, 72, 91.Google Scholar
11. Winkelmann, N. W. Jr., “Chlorpromazine in the Treatment of Neuropsychiatric Disorders”, J. Amer. Med. Ass., 1954, 155, 18.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.